Ophira Salomon, Nurit Rosenberg
Amalia Biron Research Institute of Thrombosis and Haemostasis, Sheba Medical Center, Tel Hashomer and Sackler Faculty of Medicine, Tel Aviv University, Israel. ophiras@sheba.health.gov.il
British journal of haematology 2013 AugFetal neonatal alloimmune thrombocytopenia (FNAIT) is a devastating bleeding disorder in the fetus or neonate caused by transplacental transport of maternal alloantibodies to paternal-derived antigen on fetal platelets. In Caucasians, up to 80% of FNAIT cases result from maternal immunization to human platelet antigen (HPA)-1a. New methods have developed facilitating detection of common and private antibodies against HPAs triggering FNAIT. Understanding the pathogenesis of FNAIT made it possible to develop a novel strategy to treat this disorder. To date, recombinant monoclonal antibodies directed against the β3 integrin and Fc receptors have been tested in a mouse model of FNAIT, and seem to be promising. Whether those novel treatments will eventually replace the conventional high dose immunoglobulin G in women with FNAIT is yet unknown. © 2013 John Wiley & Sons Ltd.
Ophira Salomon, Nurit Rosenberg. Predicting risk severity and response of fetal neonatal alloimmune thrombocytopenia. British journal of haematology. 2013 Aug;162(3):304-12
PMID: 23672281
View Full Text